Enhancement of the Oral Availability of Cabazitaxel Using the Cytochrome P450 3A (CYP3A) Inhibitor Ritonavir in Mice

CYP3A型 利托那韦 卡巴齐塔塞尔 药理学 最大值 药代动力学 CYP3A4型 生物利用度 化学 口服 细胞色素P450 医学 内科学 新陈代谢 生物化学 免疫学 前列腺癌 癌症 病毒载量 雄激素剥夺疗法 抗逆转录病毒疗法 人类免疫缺陷病毒(HIV)
作者
Nancy H.C. Loos,Margarida L.F. Martins,Daniëlle de Jong,Maria C. Lebre,Matthijs M. Tibben,Jos H. Beijnen,Alfred H. Schinkel
出处
期刊:Molecular Pharmaceutics [American Chemical Society]
卷期号:20 (5): 2477-2489
标识
DOI:10.1021/acs.molpharmaceut.2c01076
摘要

There is currently great interest in developing oral taxanes due to their lower costs and greater patient friendliness. We here wanted to test whether oral ritonavir, a cytochrome P450 3A (CYP3A) inhibitor, could boost the pharmacokinetics and tissue distribution of orally administered cabazitaxel (10 mg/kg) in male wild-type, Cyp3a-/-, and Cyp3aXAV (transgenic overexpression of human CYP3A4 in liver and intestine) mice. Ritonavir was initially administered at a dose of 25 mg/kg, but lower dosages of 10 and 1 mg/kg were also studied to assess the remaining amount of boosting, aiming to minimize possible side effects. Compared to the respective vehicle groups, plasma exposure of cabazitaxel (AUC0-24h) was enhanced 2.9-, 10.9-, and 13.9-fold in wild-type mice and 1.4-, 10.1-, and 34.3-fold in Cyp3aXAV mice by treatment with 1, 10, and 25 mg/kg ritonavir, respectively. Upon treatment with 1, 10, and 25 mg/kg of ritonavir, the peak plasma concentration (Cmax) was increased by 1.4-, 2.3-, and 2.8-fold in wild-type mice, while it increased by 1.7-, 4.2-, and 8.0-fold in Cyp3aXAV mice, respectively. AUC0-24h and Cmax remained unchanged in Cyp3a-/-. Biotransformation of cabazitaxel to its active metabolites still took place when coadministered with ritonavir, but this process was delayed due to the Cyp3a/CYP3A4 inhibition. These data indicate that CYP3A is the primary limiting factor in the plasma exposure to cabazitaxel and that cabazitaxel oral bioavailability could be dramatically enhanced by coadministration of an effective CYP3A inhibitor such as ritonavir. These findings could be a starting point for the setup of a clinical study, which would be needed to verify the boosting of cabazitaxel by ritonavir in humans.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
着急的笑旋完成签到,获得积分10
1秒前
周杰完成签到,获得积分10
1秒前
科研通AI5应助阿光采纳,获得10
2秒前
gezid完成签到 ,获得积分10
3秒前
3秒前
贪玩半蕾发布了新的文献求助10
4秒前
xx发布了新的文献求助10
4秒前
hanleiharry1发布了新的文献求助10
5秒前
5秒前
tutu完成签到,获得积分10
6秒前
Lucas应助wanhe采纳,获得10
7秒前
8秒前
8秒前
8秒前
Shell完成签到,获得积分10
8秒前
科目三应助科研猫采纳,获得10
8秒前
9秒前
喜悦香薇完成签到,获得积分10
9秒前
研友_VZG7GZ应助doctor_loong采纳,获得10
9秒前
Garra9822完成签到 ,获得积分10
11秒前
ypl发布了新的文献求助10
11秒前
12秒前
荷塘月色完成签到,获得积分10
12秒前
华仔应助高贵芷波采纳,获得10
12秒前
13秒前
自信又菡发布了新的文献求助10
13秒前
13秒前
MaoMao完成签到,获得积分20
13秒前
渡劫完成签到,获得积分10
13秒前
小白菜完成签到 ,获得积分10
14秒前
欣5完成签到,获得积分10
14秒前
Lucas应助小猪采纳,获得10
16秒前
xcf完成签到,获得积分20
16秒前
小孙完成签到,获得积分10
16秒前
17秒前
胖心怡完成签到,获得积分10
17秒前
复杂瑛完成签到 ,获得积分10
18秒前
19秒前
碗碗完成签到,获得积分10
20秒前
lz完成签到,获得积分10
21秒前
高分求助中
Production Logging: Theoretical and Interpretive Elements 2700
Mechanistic Modeling of Gas-Liquid Two-Phase Flow in Pipes 2500
Kelsen’s Legacy: Legal Normativity, International Law and Democracy 1000
Handbook on Inequality and Social Capital 800
Conference Record, IAS Annual Meeting 1977 610
Interest Rate Modeling. Volume 3: Products and Risk Management 600
Interest Rate Modeling. Volume 2: Term Structure Models 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3546536
求助须知:如何正确求助?哪些是违规求助? 3123667
关于积分的说明 9356348
捐赠科研通 2822331
什么是DOI,文献DOI怎么找? 1551314
邀请新用户注册赠送积分活动 723326
科研通“疑难数据库(出版商)”最低求助积分说明 713699